The innate immune system plays a dual role in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (AD): initially mounting protective responses to clear pathological
protein aggregates, but ultimately driving chronic [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- that accelerates neurodegeneration. Pattern recognition receptors
(PRRs) — including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and cytosolic DNA sensors — detect [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- ([Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and
other danger-associated molecular patterns (DAMPs), activating downstream signaling cascades involving [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX--, the [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inflammasome],
and the STING] pathway (Heneka et al., 2015) [2].
Genome-wide association studies (GWAS) have identified numerous AD risk loci in innate immune [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes — including [TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX--, CD33, INPP5D, PLCG2, ABI3, and [ABCA7[/entities/[abca7[/entities/[abca7[/entities/[abca7[/entities/[abca7--TEMP--/entities)--FIX-- — establishing neuroinflammation as a core pathogenic mechanism rather than a secondary consequence of neurodegeneration. Understanding these signaling pathways is critical for developing immunomodulatory therapies that can dampen harmful inflammation while preserving beneficial immune functions such as [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- phagocytosis and debris clearance [3].
TLR2 and [TLR4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4--TEMP--/entities)--FIX-- are the most extensively studied innate immune receptors in AD. Both recognize fibrillar and oligomeric [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- as a DAMP, initiating MyD88-dependent signaling that activates [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- and MAPK pathways (Liu et al., 2020). Upon [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- binding, [TLR4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4--TEMP--/entities)--FIX-- forms a complex with MD-2 and CD14, triggering:
The role of TLR signaling in AD is profoundly context-dependent: acute TLR activation promotes microglial phagocytosis and [Abeta clearance, while chronic activation drives sustained cytokine production, synaptic damage, and neuronal death. [TLR4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4[/entities/[tlr4--TEMP--/entities)--FIX-- polymorphisms (e.g., Asp299Gly) modify AD risk in certain populations, with hyporesponsive variants associated with reduced inflammation but potentially impaired [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance (Walter et al., 2007) [4].
TLR9, an endosomal receptor that recognizes unmethylated CpG DNA, is activated by mitochondrial DNA (mtDNA) released from damaged [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. Mitochondrial dysfunction in AD leads to mtDNA release into the cytoplasm and extracellular space, where it acts as a potent DAMP. TLR9 activation in [microglia. [Amyloid] triggers neuronal [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- through multiple routes:
Sustained [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- activation upregulates [BACE1[/[NLRP3[/[NLRP3[/[NLRP3[/[NLRP3[/[NLRP3[/[NLRP3[/[NLRP3[/NLRP3] inflammasome activation requires two sequential signals:
A critical pathogenic mechanism was revealed by the discovery that ASC specks released from pyroptotic [microglia. ASC specks are remarkably stable, persist in the extracellular space, and can be phagocytosed by neighboring [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- | CANTOS trial showed reduced cardiovascular events; secondary analysis for AD in progress |
| NT-0796 | Brain-penetrant [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inhibitor | Phase I | Designed for CNS inflammatory conditions |
The stimulator of interferon genes ([STING[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway--TEMP--/entities)--FIX-- pathway is a cytosolic DNA-sensing mechanism activated by cyclic GMP-AMP synthase (cGAS), which detects double-stranded DNA in the cytoplasm. In AD, mitochondrial and nuclear DNA released from damaged [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- activates the cGAS-[STING[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway--TEMP--/entities)--FIX-- pathway, driving type I interferon (IFN-I) production and interferon-stimulated gene (ISG) expression (Xie et al., 2023) [7].
[STING[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway--TEMP--/entities)--FIX-- activation contributes to tau] pathology through interferon-mediated upregulation of kinases that phosphorylate tau, including GSK-3beta and [CDK5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5[/entities/[cdk5--TEMP--/entities)--FIX--. In tauopathy mouse models, genetic deletion of [STING[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway--TEMP--/entities)--FIX-- reduces tau phosphorylation, neuroinflammation, and neurodegeneration. [STING[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway--TEMP--/entities)--FIX-- inhibitors (H-151, C-178) are in preclinical development for neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases [8].
[STING[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway[/entities/[sting-pathway--TEMP--/entities)--FIX-- activation in [microglia promotes a neurotoxic inflammatory phenotype while impairing phagocytic function. The resulting type I interferon response upregulates complement components, chemokines (CXCL10, CCL2), and antigen presentation molecules (MHC-II), amplifying the broader neuroinflammatory cascade. This may also promote adaptive immune cell infiltration into the CNS, bridging innate and [adaptive immunity[/mechanisms/[adaptive-immunity[/mechanisms/[adaptive-immunity[/mechanisms/[adaptive-immunity[/mechanisms/[adaptive-immunity--TEMP--/mechanisms)--FIX-- in AD [9].
[TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX-- (triggering receptor expressed on myeloid cells 2) is expressed primarily on [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--" title="[Keren-Shaul H, Spinrad A, Weiner A, et al. [A unique microglia type associated
with restricting development of Alzheimer's Disease]https://pubmed.ncbi.nlm.nih.gov/28602351/)">11.
The complement system provides innate immune defense through opsonization, inflammation, and membrane attack complex (MAC) formation. In AD, complement components C1q, C3, and C4 are significantly upregulated in brain tissue, particularly around amyloid plaques and degenerating synapses (Hong et al., 2016) [12].
C1q binds to synapses in an age- and [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---dependent manner, initiating the classical complement cascade that culminates in C3b/iC3b deposition on synaptic membranes. Complement receptor 3 (CR3/CD11b) on [microglia">13.
Key findings:
| Target | Approach | Stage | Rationale |
|---|---|---|---|
| C1q | Anti-C1q antibody (ANX005) | Phase II | Blocks classical pathway initiation; preserves lectin/alternative pathways |
| C3 | C3 inhibitor (AMY-101, pegcetacoplan) | Preclinical (AD) | Blocks all complement pathways; risk of infection |
| CR3 | CR3 antagonists | Preclinical | Blocks [microglial phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis[/mechanisms/[microglial-phagocytosis--TEMP--/mechanisms)--FIX-- of tagged synapses |
| C5 | Anti-C5 (eculizumab derivatives) | Preclinical (AD) | Blocks MAC formation and C5a-mediated inflammation |
However, complement also facilitates [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance, so therapeutic strategies must carefully balance synapse protection against impairment of beneficial clearance functions [14].
CD33 (Siglec-3) is a sialic acid-binding immunoglobulin-like lectin expressed on [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--" title="Parhizkar S, Bhatt DL, et al. [TREM2 agonism in preclinical models and the INVOKE-2 clinical trial)">15.
The oversimplified M1 (pro-inflammatory) / M2 (anti-inflammatory) classification has been replaced by an appreciation of multiple distinct microglial transcriptomic and functional states revealed by single-cell RNA sequencing:
Although AD has been primarily considered an innate immune disease, accumulating evidence implicates adaptive immunity:
The innate-adaptive immune interface, particularly the role of MHC-II-expressing [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--" title="Leng F, Edison P. [neuroinflammation and microglial activation in [Alzheimer] disease: where do we go from here?)">[18].
The dual protective/destructive nature of innate immunity in AD necessitates precision approaches rather than broad immunosuppression. Multiple [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials of NSAIDs (non-steroidal anti-inflammatory drugs) failed in AD, likely because these agents suppress both harmful and protective immune functions. Current strategies include:
Inflammatory biomarkers can identify patients with prominent neuroinflammation and guide therapeutic timing:
Initiating anti-inflammatory therapy during the transition from protective to destructive inflammation — potentially identifiable through longitudinal biomarker monitoring — may provide the greatest therapeutic benefit [1].
The study of Innate Immune Signaling Pathways In [Alzheimer]'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development [2].
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [3].
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 18 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 67% |
| Mechanistic Completeness | 50% |
Overall Confidence: 51%